• CEL-SCI Corporation (NYSE:CVM) announced Thursday that the FDA agreed to its proposal to use the PD-L1 biomarker status in selecting patients for a registrational trial for its lead cancer therapy, Multikine.
• Accordingly, the 212-subject confirmatory trial is expected to enroll newly

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。